Patents by Inventor Norio NONOMURA
Norio NONOMURA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11951125Abstract: One drug (solid preparation) 100 of the present invention is a drug for a disease of kidney that contains a silicon fine particle, an aggregate of the silicon fine particles, or a crystal grain of silicon having a hydrogen-generating ability. Hydrogen generated from the silicon fine particle in the drug can contribute to the prevention and/or treatment of the kidney disease.Type: GrantFiled: April 21, 2021Date of Patent: April 9, 2024Assignee: OSAKA UNIVERSITYInventors: Hikaru Kobayashi, Yuki Kobayashi, Ryoichi Imamura, Norio Nonomura
-
Patent number: 11932696Abstract: The present invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8.Type: GrantFiled: December 28, 2020Date of Patent: March 19, 2024Assignees: SHIONOGI & CO., LTD., OSAKA UNIVERSITYInventors: Tetsuya Yoshida, Yujiro Kidani, Mitsunobu Matsumoto, Takayuki Kanazawa, Satomi Shinonome, Kanji Hojo, Naganari Ohkura, Shimon Sakaguchi, Atsushi Tanaka, Hisashi Wada, Atsunari Kawashima, Norio Nonomura
-
Publication number: 20240008761Abstract: An evaluation method is performed by an arithmetic circuit and includes obtainment processing (S1), evaluation processing (S2), and presentation processing (S3). The obtainment processing (S1) obtains: image information on a sectional image representing an interested section of an organism including a target section of a testis of the organism generated by use of magnetic resonance of hydrogen atoms; and concentration information on a creatine concentration in the interested section measured by use of magnetic resonance based on chemical exchange saturation transfer. The evaluation processing (S2) generates an evaluation image representing a distribution of evaluation results of a testicular function in the target section based on the concentration information. The presentation processing (S3) presents the sectional image and the evaluation image.Type: ApplicationFiled: November 25, 2021Publication date: January 11, 2024Inventors: Hidetaka KIOKA, Yusuke TAKAHASHI, Shinichiro FUKUHARA, Yasushi SAKATA, Norio NONOMURA, Seiji TAKASHIMA, Shigeyoshi SAITO
-
Publication number: 20230053846Abstract: A problem to be addressed by the present invention is to provide: a method for detecting bone metastasis of cancer (excluding castration resistant prostate cancer) in a simple and highly accurate manner; and a reagent that can be used in the method. Bone metastasis of cancer (excluding castration resistant prostate cancer) is detected by measuring an intact growth and differentiation factor 15 (GDF15) propeptide level, a GDF15 propeptide fragment level, and the total of an intact GDF15 propeptide level and a GDF15 propeptide fragment level in a sample. The above described method for detecting bone metastasis of cancer includes a method for detecting bone metastasis of prostate cancer other than castration resistant prostate cancer, renal cancer, lung cancer, breast cancer, thyroid cancer, pancreatic cancer, bladder cancer, colon cancer, melanoma, myeloma, or lymphoma.Type: ApplicationFiled: November 13, 2020Publication date: February 23, 2023Applicants: OSAKA UNIVERSITY, TOSOH CORPORATIONInventors: Motohide UEMURA, Norio NONOMURA, Takeshi UJIKE, Shohei MYOBA, Norihisa OHTAKE
-
Publication number: 20220178932Abstract: An object of the invention is to provide a method for detecting cancer in a simple and highly accurate manner, and a reagent that can be used in the method. A method for detecting cancer (excluding renal cell cancer), which comprises measuring the level of Azurocidin (AZU1) in a sample, in which it is determined that cancer is detected when a measured value exceeds a preset reference value. The cancer is preferably selected from the group consisting of stomach cancer, breast cancer, colorectal cancer, and lung cancer. A reagent containing an antibody that specifically recognizes AZU1 is used in detecting cancer (excluding renal cell cancer).Type: ApplicationFiled: April 15, 2020Publication date: June 9, 2022Applicants: JAPANESE FOUNDATION FOR CANCER RESEARCH, OSAKA UNIVERSITY, TOSOH CORPORATIONInventors: Koji UEDA, Naomi OHNISHI, Kazutake TSUJIKAWA, Norio NONOMURA, Motohide UEMURA, Kentaro JINGUSHI, Norihisa OHTAKE, Yasutoshi KAWAI
-
Publication number: 20220088064Abstract: One drug (preparation) of the present invention is a drug for a reproductive disorder containing a silicon fine particle, an aggregate of silicon fine particles or a crystal grain of silicon having a hydrogen-generating ability. Hydrogen generated from the silicon fine particle in the drug can contribute to the prevention and/or treatment of reproductive disorder.Type: ApplicationFiled: November 29, 2019Publication date: March 24, 2022Applicant: OSAKA UNIVERSITYInventors: Ryoichi IMAMURA, Hikaru KOBAYASHI, Yuki KOBAYASHI, Shinichiro FUKUHARA, Yusuke INAGAKI, Norio NONOMURA
-
Patent number: 11226334Abstract: [Problem] To provide a method for detecting high-risk prostate cancer, for the purpose of providing useful information, such as necessity of biopsy, to a test-positive patient in a PSA test. [Solution] The method for detecting high-risk prostate cancer according to the present invention comprises reacting a PSA contained in a sample composed of urine collected from a human body which is suspected to be suffering from prostate cancer with (1) a fucose ?1?6 affinitive lectin which has a characteristic property that the lectin has affinity expressed by a binding constant of 1.0×104 M?1 or more (at 25° C.) for an ?1?6 fucose sugar chain No. 405. The fucose ?1?6 affinitive lectin is preferably (2) a fucose ?1?6 specific lectin which has a characteristic property that the lectin has a binding constant of 1.0×104 M?1 or less (at 25° C.) for a sugar chain No. 003 that does not contain ?1?6 fucose and a glycolipid-type sugar chain No. 909 that does not contain ?1?6 fucose.Type: GrantFiled: February 3, 2017Date of Patent: January 18, 2022Assignees: J-CHEMICAL, INC., OSAKA UNIVERSITYInventors: Yuka Kobayashi, Kazutoshi Fujita, Norio Nonomura, Eiji Miyoshi
-
Publication number: 20210275578Abstract: One drug (solid preparation) 100 of the present invention is a drug for a disease of kidney that contains a silicon fine particle, an aggregate of the silicon fine particles, or a crystal grain of silicon having a hydrogen-generating ability. Hydrogen generated from the silicon fine particle in the drug can contribute to the prevention and/or treatment of the kidney disease.Type: ApplicationFiled: April 21, 2021Publication date: September 9, 2021Inventors: Hikaru KOBAYASHI, Yuki KOBAYASHI, Ryoichi IMAMURA, Norio NONOMURA
-
Patent number: 11103527Abstract: One drug (solid preparation) 100 of the present invention is a drug for a disease of kidney that contains a silicon fine particle, an aggregate of the silicon fine particles, or a crystal grain of silicon having a hydrogen-generating ability. Hydrogen generated from the silicon fine particle in the drug can contribute to the prevention and/or treatment of the kidney disease.Type: GrantFiled: July 4, 2018Date of Patent: August 31, 2021Assignee: Osaka UniversityInventors: Hikaru Kobayashi, Yuki Kobayashi, Ryoichi Imamura, Norio Nonomura
-
Publication number: 20210115148Abstract: The present invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8.Type: ApplicationFiled: December 28, 2020Publication date: April 22, 2021Applicants: Shionogi & Co., Ltd., Osaka UniversityInventors: Tetsuya Yoshida, Yujiro Kidani, Mitsunobu Matsumoto, Takayuki Kanazawa, Satomi Shinonome, Kanji Hojo, Naganari Ohkura, Shimon Sakaguchi, Atsushi Tanaka, Hisashi Wada, Atsunari Kawashima, Norio Nonomura
-
Publication number: 20210047421Abstract: The present invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8.Type: ApplicationFiled: October 30, 2020Publication date: February 18, 2021Applicants: Shionogi & Co., Ltd., Osaka UniversityInventors: Tetsuya Yoshida, Yujiro Kidani, Mitsunobu Matsumoto, Takayuki Kanazawa, Satomi Shinonome, Kanji Hojo, Naganari Ohkura, Shimon Sakaguchi, Atsushi Tanaka, Hisashi Wada, Atsunari Kawashima, Norio Nonomura
-
Publication number: 20200264182Abstract: [Problem] To provide a method for detecting prostate cancer, the method having a higher degree of certainty than the PSA blood test and providing measurement values that correlate with risk classification. [Solution] This method for detecting prostate cancer is characterized in that: the method includes reacting fucose ?1?6 specific lectin and fucosylated PSA contained in a sample constituted of serum collected from a subject, and detecting the reacted lectin; and the pH in at least one step of the group consisting of the reaction step for reacting the fucosylated PSA and the lectin and processing steps thereafter is adjusted to above 8.5 and less than 11.0.Type: ApplicationFiled: September 21, 2018Publication date: August 20, 2020Inventors: Kazutoshi FUJITA, Norio NONOMURA, Eiji MIYOSHI, Yuka KOBAYASHI
-
Publication number: 20200232973Abstract: The disclosure provides a method of measuring an efficacy of a drug composition for cancer and a method for treating a cancer by administering to a subject an effective amount of a pharmaceutical composition having a polypeptide that binds to a peptide produced by cDNA of GenBank ACC No. NM_005201.3 or NM_007720.2.Type: ApplicationFiled: January 2, 2020Publication date: July 23, 2020Applicants: Shionogi & Co., Ltd., Osaka UniversityInventors: Tetsuya Yoshida, Yujiro Kidani, Mitsunobu Matsumoto, Takayuki Kanazawa, Satomi Shinonome, Kanji Hojo, Naganari Ohkura, Shimon Sakaguchi, Atsushi Tanaka, Hisashi Wada, Atsunari Kawashima, Norio Nonomura
-
Publication number: 20200222463Abstract: The disclosure provides a pharmaceutical composition with a polypeptide that binds to a peptide produced by cDNA of GenBank ACC No. NM_005201.3 or NM_007720.2, and methods of use thereof.Type: ApplicationFiled: January 2, 2020Publication date: July 16, 2020Applicants: Shionogi & Co., Ltd., Osaka UniversityInventors: Tetsuya Yoshida, Yujiro Kidani, Mitsunobu Matsumoto, Takayuki Kanazawa, Satomi Shinonome, Kanji Hojo, Naganari Ohkura, Shimon Sakaguchi, Atsushi Tanaka, Hisashi Wada, Atsunari Kawashima, Norio Nonomura
-
Publication number: 20200179439Abstract: One drug (solid preparation) 100 of the present invention is a drug for a disease of kidney that contains a silicon fine particle, an aggregate of the silicon fine particles, or a crystal grain of silicon having a hydrogen-generating ability. Hydrogen generated from the silicon fine particle in the drug can contribute to the prevention and/or treatment of the kidney disease.Type: ApplicationFiled: July 4, 2018Publication date: June 11, 2020Inventors: Hikaru KOBAYASHI, Yuki KOBAYASHI, Ryoichi IMAMURA, Norio NONOMURA
-
Patent number: 10550191Abstract: The present invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8.Type: GrantFiled: November 7, 2018Date of Patent: February 4, 2020Assignees: Shionogi & Co., Ltd., Osaka UniversityInventors: Tetsuya Yoshida, Yujiro Kidani, Mitsunobu Matsumoto, Takayuki Kanazawa, Satomi Shinonome, Kanji Hojo, Naganari Ohkura, Shimon Sakaguchi, Atsushi Tanaka, Hisashi Wada, Atsunari Kawashima, Norio Nonomura
-
Publication number: 20190310258Abstract: Provided is a method wherein an affected tissue and a normal tissue obtained from the vicinity of the affected tissue are left at rest in a culture medium, and a disease-specific biomarker is searched for in an exudate therefrom. A biomarker specific to renal cell carcinoma has been found by this method.Type: ApplicationFiled: October 26, 2017Publication date: October 10, 2019Applicants: JAPANESE FOUNDATION FOR CANCER RESEARCH, OSAKA UNIVERSITYInventors: Koji Ueda, Naomi Ohnishi, Norio Nonomura, Motohide Uemura, Kazutoshi Fujita, Kazutake Tsujikawa, Kentarou Jingushi
-
Publication number: 20190071508Abstract: The present invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8.Type: ApplicationFiled: November 7, 2018Publication date: March 7, 2019Applicants: SHIONOGI & CO., LTD., OSAKA UNIVERSITYInventors: Tetsuya YOSHIDA, Yujiro KIDANI, Mitsunobu MATSUMOTO, Takayuki KANAZAWA, Satomi SHINONOME, Kanji HOJO, Naganari OHKURA, Shimon SAKAGUCHI, Atsushi TANAKA, Hisashi WADA, Atsunari KAWASHIMA, Norio NONOMURA
-
Publication number: 20190049451Abstract: [Problem] To provide a method for detecting high-risk prostate cancer, for the purpose of providing useful information, such as necessity of biopsy, to a test-positive patient in a PSA test. [Solution] The method for detecting high-risk prostate cancer according to the present invention comprises reacting a PSA contained in a sample composed of urine collected from a human body which is suspected to be suffering from prostate cancer with (1) a fucose ?1?6 affinitive lectin which has a characteristic property that the lectin has affinity expressed by a binding constant of 1.0×104 M?1 or more (at 25° C.) for an ?1?6 fucose sugar chain No. 405. The fucose ?1?6 affinitive lectin is preferably (2) a fucose ?1?6 specific lectin which has a characteristic property that the lectin has a binding constant of 1.0×104 M?1 or less (at 25° C.) for a sugar chain No. 003 that does not contain ?1?6 fucose and a glycolipid-type sugar chain No. 909 that does not contain ?1?6 fucose.Type: ApplicationFiled: February 3, 2017Publication date: February 14, 2019Applicants: J-Oil Mills, Inc., Osaka UniversityInventors: Yuka KOBAYASHI, Kazutoshi FUJITA, Norio NONOMURA, Eiji MIYOSHI